These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24189371)

  • 1. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
    Safaeian M; Porras C; Pan Y; Kreimer A; Schiller JT; Gonzalez P; Lowy DR; Wacholder S; Schiffman M; Rodriguez AC; Herrero R; Kemp T; Shelton G; Quint W; van Doorn LJ; Hildesheim A; Pinto LA;
    Cancer Prev Res (Phila); 2013 Nov; 6(11):1242-50. PubMed ID: 24189371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
    Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
    Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
    J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
    Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
    J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
    Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA
    Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.
    Safaeian M; Porras C; Schiffman M; Rodriguez AC; Wacholder S; Gonzalez P; Quint W; van Doorn LJ; Sherman ME; Xhenseval V; Herrero R; Hildesheim A;
    J Natl Cancer Inst; 2010 Nov; 102(21):1653-62. PubMed ID: 20944077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
    LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
    Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
    Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR;
    J Natl Cancer Inst; 2018 Feb; 110(2):205-12. PubMed ID: 28954299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.
    Robbins HA; Li Y; Porras C; Pawlita M; Ghosh A; Rodriguez AC; Schiffman M; Wacholder S; Kemp TJ; Gonzalez P; Schiller J; Lowy D; Esser M; Matys K; Quint W; van Doorn LJ; Herrero R; Pinto LA; Hildesheim A; Waterboer T; Safaeian M
    BMC Infect Dis; 2014 Mar; 14():120. PubMed ID: 24588945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
    Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
    Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies.
    Kreimer AR; Herrero R; Sampson JN; Porras C; Lowy DR; Schiller JT; Schiffman M; Rodriguez AC; Chanock S; Jimenez S; Schussler J; Gail MH; Safaeian M; Kemp TJ; Cortes B; Pinto LA; Hildesheim A; Gonzalez P;
    Vaccine; 2018 Aug; 36(32 Pt A):4774-4782. PubMed ID: 29366703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
    Kreimer AR; Rodriguez AC; Hildesheim A; Herrero R; Porras C; Schiffman M; González P; Solomon D; Jiménez S; Schiller JT; Lowy DR; Quint W; Sherman ME; Schussler J; Wacholder S;
    J Natl Cancer Inst; 2011 Oct; 103(19):1444-51. PubMed ID: 21908768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
    J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A; Bissett SL; Miller E; Beddows S
    PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.
    Coseo SE; Porras C; Dodd LE; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
    Sex Transm Dis; 2011 Oct; 38(10):976-82. PubMed ID: 21934576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.